Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109
NCT ID: NCT01640912
Last Updated: 2014-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
15 participants
INTERVENTIONAL
2012-06-30
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109
NCT01780077
Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
NCT01038297
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars
NCT02246465
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
NCT01037985
Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance
NCT03880058
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RXI-109
RXI-109
Single intradermal injection of RXI-109 at incision sites
Placebo
Placebo
Single intradermal injection of placebo at incision sites
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RXI-109
Single intradermal injection of RXI-109 at incision sites
Placebo
Single intradermal injection of placebo at incision sites
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must be a good surgical candidate for an elective abdominoplasty
* Subjects must not be pregnant or lactating and utilize an effective method of contraception (if child-bearing potential exists)
Exclusion Criteria
* BMI greater than 35 at screening
* Use of tobacco or nicotine-containing products within the month prior to enrollment and while on study
* Any medical condition or current therapy which would make the subject unsuitable for this study in the opinion of the PI
21 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RXi Pharmaceuticals, Corp.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RXI-109-1201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.